How Healthcare & Life Sciences Transactions Structure Indemnity Risk

Most healthcare and life sciences transactions must comply with the Hart-Scott-Rodino Act (HSR Act) if they meet size-of-transaction thresholds, the Stark Law and Anti-Kickback Statute if they involve physician referral arrangements or payment terms, state corporate practice of medicine prohibitions, and the Health Insurance Portability and Accountability Act (HIPAA) if protected health information is transferred. Parties must file HSR notifications with the Federal Trade Commission and Department of Justice if the transaction exceeds the current threshold (adjusted annually), and failure to file or comply with waiting periods can expose parties to criminal penalties and transaction unwinding. State-specific licensing transfers, pharmacy board approvals, and hospital credentialing requirements add additional procedural steps that vary by jurisdiction and asset type.

FDA approval status and regulatory classification directly determine whether a transaction can close and what representations, warranties, and indemnification provisions apply post-closing. For pharmaceutical and biologic assets, the FDA requires that the acquiring party demonstrate manufacturing capability, quality assurance systems, and compliance with current good manufacturing practices (cGMP) before product approvals transfer, and delayed cGMP certification can postpone closing or trigger escrow holdback provisions. Medical device companies must ensure that 510(k) premarket notifications or premarket approval pathways remain on track during transition; if a device loses regulatory clearance or faces warning letters, the transaction price may be adjusted or the deal may terminate based on materiality clauses.

Asset purchases transfer specific healthcare assets, intellectual property, contracts, and patient records while leaving liabilities with the seller, offering the buyer regulatory continuity and liability protection but requiring state licensing transfers and patient notification compliance. Stock purchases transfer the entire entity and all liabilities, often streamlining regulatory approval but exposing the buyer to unknown or contingent liabilities and requiring successor-in-interest determinations under Medicare and Medicaid rules. In practice, healthcare buyers often prefer asset structures to isolate regulatory risk, but sellers may resist if they have significant undisclosed liabilities or wish to retain certain operations.

Licensing arrangements allow the acquirer to use specific intellectual property, drug formulations, or medical device designs without acquiring the underlying entity, reducing regulatory burden and capital requirements but limiting control and creating ongoing royalty or milestone obligations. Joint ventures combine assets and operations under shared governance, common in life sciences research partnerships and healthcare delivery networks, but require careful governance documentation and compliance with federal Anti-Kickback Statute provisions if physician owners are involved. These structures often appeal when regulatory approval is uncertain or when parties wish to preserve independence while achieving operational synergies.

HSR filing is required if the transaction exceeds the size-of-transaction threshold (currently $111.4 million, adjusted annually) and the parties meet the size-of-person test, requiring notification to the FTC and DOJ before closing. Failure to file or proceeding before the 30-day waiting period expires (or longer if the agencies issue a second request) can result in criminal penalties up to $16,000 per day of violation, forced transaction unwinding, and private party damages claims. Parties must also disclose all prior communications regarding the transaction, competitive analyses, and board materials, creating significant discovery exposure if the deal later faces challenge.

State attorneys general, including New York's, maintain independent authority to challenge healthcare transactions under state antitrust laws and consumer protection statutes, and may initiate separate investigations or litigation even after federal approval. In New York courts, healthcare transaction challenges may be brought in the Commercial Division of the Supreme Court, where discovery timelines and motion practice are accelerated compared to standard civil litigation, and preliminary injunction standards require a showing of likelihood of success on the merits, irreparable harm, and balance of equities. A party defending a transaction in New York may face summary judgment motions on market definition and competitive impact within 6 to 9 months of filing, creating pressure to resolve or restructure the deal early in the litigation posture.

Critical representations include regulatory compliance (FDA approvals current, no warning letters or import alerts, manufacturing facilities meet cGMP standards), healthcare provider credentials (medical licenses valid, no exclusions from Medicare or Medicaid, malpractice insurance current), intellectual property (patents valid and enforceable, no infringement claims pending, freedom to operate for key products), and data security and privacy (HIPAA compliance, no prior breaches, data handling procedures documented). Buyers typically insist on survival periods of 18 to 24 months for general representations and 3 to 6 years for tax and environmental representations, with escrow holdbacks of 10 to 20 percent of purchase price to secure indemnification obligations. Sellers often negotiate caps on indemnification exposure, baskets (minimum threshold before indemnification applies), and carve-outs for known risks disclosed in schedules.

Parties should obtain and verify all regulatory approvals (FDA, state licensing boards, HSR clearance, state attorney general sign-offs if required), conduct final compliance audits and risk assessments, obtain third-party consents from payers, referring physicians, and key contracts, ensure HIPAA Business Associate Agreement amendments are signed, and prepare transition services agreements and employee benefit assumption documents. A common procedural timeline requires 90 to 180 days from signing to closing, depending on the complexity of regulatory approvals and the number of third-party consents required.